Regulatory
Report
Interim report Q3 2026
November 5, 2026
Press releases
Press Releases
This section contains official press releases issued by Egetis. These announcements include regulatory updates, corporate developments and information disclosed in accordance with applicable market regulations.
Search below for our latest press releases and company reports
Regulatory
Corporate Action
Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals
November 5, 2026
Regulatory
Corporate Action
Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million
November 4, 2026
Corporate Information
Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency
October 27, 2026
Corporate Information
Egetis’ Nomination Committee for the 2027 Annual General Meeting
October 21, 2026
Corporate Information
International retrospective cohort study published on “molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)”
October 16, 2026
Regulatory
Corporate Action
Changes in number of shares and votes in Egetis Therapeutics
September 30, 2026
Regulatory
Corporate Information
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
September 28, 2026
Corporate Information
Emcitate® (tiratricol) Presentations at ETA and ESPE Congresses in September 2026
September 4, 2026
Corporate Information
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
September 3, 2026
Corporate Information
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
September 3, 2026
Corporate Information
Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan
August 31, 2026
Latest From LinkedIn
Explore